Abstract: Increasing number of domestic pharmaceutical companies choose to conduct clinical trials of innovative drugs in both China and US and seek to launch in overseas markets. As of June 2019, 85 products under investigational new drug (IND) application have been approved both in China and US. This paper analyzes the characteristics of these products as well as the advantages and challenges of China's enterprises conducting clinical trials of innovative drugs in both China and US.